COMMUNITY HOSPITAL ANDERSON
- Type
- Teaching hospital
- Where
- ANDERSON, IN
- Medicare CCN
- 150113
- Received
- $368,125 in 127 records, 2019 ($8,926 general, $359,198 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 11 | $8,926 |
| 2019 | Research payment | 116 | $359,198 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novo Nordisk AS | 53 | $140,252 | 2019 |
| PFIZER INC. | 44 | $69,629 | 2019 |
| AstraZeneca Pharmaceuticals LP | 5 | $58,695 | 2019 |
| Novartis Pharmaceuticals Corporation | 3 | $27,728 | 2019 |
| AstraZeneca UK Limited | 2 | $24,834 | 2019 |
| Merck Sharp & Dohme LLC | 3 | $16,600 | 2019 |
| Amgen Inc. | 2 | $10,000 | 2019 |
| Celgene Corporation | 2 | $7,125 | 2019 |
| BioFire Diagnostics, LLC | 1 | $5,850 | 2019 |
| Eli Lilly and Company | 3 | $4,583 | 2019 |
| Stryker Corporation | 4 | $2,037 | 2019 |
| Helena Laboratories Corporation | 2 | $374 | 2019 |
| FUJIFILM Healthcare Americas Corporation | 2 | $289 | 2019 |
| SPS Medical Supply Corp. | 1 | $125 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 116 | $359,198 |
| Gift | 9 | $8,551 |
| Space rental or facility fees (teaching hospital only) | 1 | $250 |
| Education | 1 | $125 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | AstraZeneca UK Limited | $3,402 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | Stryker Corporation | $1,281 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,025 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | Stryker Corporation | $368 | Gift | In-kind items and services | PROFORM Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Stryker Corporation | $368 | Gift | In-kind items and services | PRIME TC TRANSPORT CHAIR Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $18 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-23 | Novo Nordisk AS | $14,419 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-17 | Novo Nordisk AS | $52 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-12-12 | PFIZER INC. | $463 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-03 | Novo Nordisk AS | $11,131 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-21 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Celgene Corporation | $375 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Connect MM- The Multiple Myeloma Disease Registry (OS002982) | 2019 |
| 2019-11-19 | Novo Nordisk AS | $49 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-13 | PFIZER INC. | $463 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-12 | PFIZER INC. | $785 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2019 |
| 2019-11-06 | PFIZER INC. | $375 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $375 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $375 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $375 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $375 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-06 | PFIZER INC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-01 | SPS Medical Supply Corp. | $125 | Education | Cash or cash equivalent | 2019 | ||
| 2019-10-29 | Novo Nordisk AS | $20,468 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-10-23 | PFIZER INC. | $4,500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $694 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-18 | AstraZeneca Pharmaceuticals LP | $6,459 | Research payment | Cash or cash equivalent | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-10-02 | PFIZER INC. | $231 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-27 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-26 | Novo Nordisk AS | $14,673 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-09-23 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-23 | Novo Nordisk AS | $19 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-23 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-20 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-17 | Novo Nordisk AS | $64 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-17 | Novo Nordisk AS | $18 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-11 | PFIZER INC. | $586 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-09 | FUJIFILM Healthcare Americas Corporation | $59 | Gift | In-kind items and services | ESD - Core Endoscopy Device, Medical Device | 2019 | |
| 2019-09-05 | BioFire Diagnostics, LLC | $5,850 | Gift | In-kind items and services | BioFire FilmArray Pneumonia 30 Pouch Kit (RFIT-ASY-0144) Device, Clinical Diagnostics | 2019 | |
| 2019-08-30 | Novo Nordisk AS | $6,866 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-08-29 | Novo Nordisk AS | $49 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-28 | PFIZER INC. | $1,636 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-27 | Eli Lilly and Company | $591 | Research payment | In-kind items and services | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN | 2019 | |
| 2019-08-22 | Novo Nordisk AS | $54 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-22 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-22 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-22 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-16 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-14 | PFIZER INC. | $2,196 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-09 | Amgen Inc. | $1,000 | Research payment | Cash or cash equivalent | Cognitive Interview and Usability Testing of QoL Measures in an ePRO Format for a Heart Failure Clinical Program | 2019 | |
| 2019-08-02 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-07-30 | Novo Nordisk AS | $13,441 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-07-25 | PFIZER INC. | $2,880 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2019 |
| 2019-07-24 | PFIZER INC. | $1,049 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-17 | PFIZER INC. | $231 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-16 | FUJIFILM Healthcare Americas Corporation | $230 | Gift | In-kind items and services | ESD - Core Endoscopy Device, Medical Device | 2019 | |
| 2019-07-16 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-07-02 | PFIZER INC. | $2,885 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-06-26 | PFIZER INC. | $586 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-06-25 | Novo Nordisk AS | $14,030 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-06-12 | AstraZeneca Pharmaceuticals LP | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-06-07 | Helena Laboratories Corporation | $190 | Gift | In-kind items and services | 2019 | ||
| 2019-06-07 | Helena Laboratories Corporation | $183 | Gift | In-kind items and services | 2019 | ||
| 2019-05-31 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-05-31 | Novo Nordisk AS | $49 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-05-30 | Merck Sharp & Dohme LLC | $6,300 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-05-29 | PFIZER INC. | $2,680 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-05-28 | Novo Nordisk AS | $11,941 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-05-28 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-05-24 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-05-22 | Celgene Corporation | $6,750 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MM | 2019 |
| 2019-05-22 | PFIZER INC. | $689 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-05-15 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-05-08 | PFIZER INC. | $1,275 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-05-07 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-05-02 | PFIZER INC. | $3,456 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2019 |
| 2019-05-01 | PFIZER INC. | $2,196 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-29 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-25 | Novo Nordisk AS | $6,096 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-04-22 | Novartis Pharmaceuticals Corporation | $22,527 | Research payment | Cash or cash equivalent | ARZERRA Drug, HEMATOLOGY | A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED | 2019 |
| 2019-04-22 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-17 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-17 | Novo Nordisk AS | $32 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-17 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-17 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-17 | Novo Nordisk AS | $18 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-04-11 | Novartis Pharmaceuticals Corporation | $4,125 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | OBSERVATIONAL REGISTRY OF TREATMENT PATTERNS IN US HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION | 2019 |
| 2019-04-10 | PFIZER INC. | $4,085 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-27 | PFIZER INC. | $818 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-26 | Novo Nordisk AS | $7,826 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-03-26 | Eli Lilly and Company | $356 | Research payment | In-kind items and services | A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHR | 2019 | |
| 2019-03-20 | PFIZER INC. | $3,894 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-13 | PFIZER INC. | $648 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-04 | PFIZER INC. | $689 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-02-26 | Novo Nordisk AS | $6,052 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-02-21 | Merck Sharp & Dohme LLC | $7,800 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-02-20 | PFIZER INC. | $1,991 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-02-20 | Novartis Pharmaceuticals Corporation | $1,076 | Research payment | Cash or cash equivalent | GILENYA Drug, NEUROSCIENCE | LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY ST | 2019 |
| 2019-02-13 | PFIZER INC. | $7,300 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-02-08 | Novo Nordisk AS | $1 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-02-07 | AstraZeneca Pharmaceuticals LP | $48,181 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Eval | 2019 |
| 2019-02-04 | PFIZER INC. | $3,390 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-01-31 | PFIZER INC. | $2,932 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2019 |
| 2019-01-28 | Eli Lilly and Company | $3,635 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2019 | |
| 2019-01-25 | Amgen Inc. | $9,000 | Research payment | Cash or cash equivalent | Cognitive Interview and Usability Testing of QoL Measures in an ePRO Format for a HF RCT | 2019 | |
| 2019-01-24 | Novo Nordisk AS | $12,202 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-01-16 | PFIZER INC. | $10,563 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-01-15 | AstraZeneca Pharmaceuticals LP | $2,779 | Research payment | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai | 2019 |
| 2019-01-11 | AstraZeneca UK Limited | $21,432 | Research payment | Cash or cash equivalent | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Anderson, IN, county Madison County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Anderson, IN | County Madison County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 55,367 | 131,900 | 6,851,073 |
| Population, 2020 census P1 | 54,788 | 130,129 | 6,785,528 |
| Median age B01002 | 38.9 | 40.9 | 38.1 |
| Under 18 B01001 | 20.9% | 21.4% | 23.3% |
| 65 and over B01001 | 19.3% | 18.8% | 16.8% |
| Households B11001 | 24,218 | 53,429 | 2,716,009 |
| Foreign born B05002 | 2.8% | 2.1% | 6.3% |
| Median household income B19013 | $46,909 | $63,037 | $71,957 |
| Median family income B19113 | $63,417 | $78,904 | $90,767 |
| Per capita income B19301 | $28,833 | $33,926 | $38,351 |
| Poverty rate B17001 | 21.0% | 13.4% | 12.3% |
| Unemployment rate B23025 | 7.3% | 5.9% | 4.3% |
| Civilian labor force B23025 | 26,008 | 64,421 | 3,472,016 |
| Mean commute (minutes) B08013 | 24.7 | 26.3 | 24.1 |
| Bachelor's degree or higher B15003 | 15.7% | 20.5% | 29.5% |
| Housing units B25001 | 27,483 | 59,301 | 2,976,568 |
| Owner-occupied B25003 | 55.5% | 70.2% | 70.6% |
| Renters B25003 | 44.5% | 29.8% | 29.4% |
| Median home value B25077 | $119,000 | $161,300 | $218,200 |
| Median gross rent B25064 | $925 | $939 | $1,062 |
| White, not Hispanic B03002 | 72.5% | 82.0% | 75.4% |
| Black B03002 | 11.6% | 6.1% | 9.1% |
| Hispanic or Latino B03002 | 8.1% | 5.4% | 8.6% |
| Asian B03002 | 0.6% | 0.7% | 2.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Anderson, IN.
Comments